<DOC>
	<DOCNO>NCT01731574</DOCNO>
	<brief_summary>This trial investigate potential drug-drug interaction dapivirine vaginal Ring-004 vaginally administer miconazole nitrate , evaluate safety co-administration dapivirine vaginal ring miconazole nitrate healthy , HIV-negative woman .</brief_summary>
	<brief_title>DDI Potential : Dapivirine Vaginal Ring Miconazole Nitrate</brief_title>
	<detailed_description />
	<mesh_term>Miconazole</mesh_term>
	<criteria>1 . Women 18 â‰¤ 40 year age give write informed consent 2 . Available visit consent follow procedure schedule trial 3 . Healthy , base medical history , vital sign , physical examination , urinalysis ( dipstick microscopy ( indicate ) ) , laboratory evaluation genital infection ( bacterial vaginosis , gonorrhoea , chlamydia trichomonas ) , laboratory evaluation haematology chemistry 4 . HIVnegative determine HIV test time enrolment 5 . On stable form contraception , define : A stable oral contraceptive regimen least 2 month prior enrolment , OR Transdermal contraceptive patch least 3 month prior enrolment , OR Longacting progestin least 6 month prior enrolment , OR An IUD insert ( vaginal gynaecological complaint associate use ) least 3 month prior enrolment , OR Have undergone surgical sterilisation least 3 month prior enrolment , AND willing use oral contraceptive necessary delay menstruation vaginal sampling period 6 . Upon pelvic examination time enrolment , cervix vagina appear normal determined Investigator/Physician 7 . Asymptomatic genital infection time enrolment ( woman diagnose treatable STI , either clinically laboratory test time screening , must receive treatment least 2 week prior enrolment ) 8 . Willing refrain use topical medication , vaginal product object , include female condom , tampon , cotton wool , rag , diaphragm , cervical cap ( vaginal barrier method ) , douche , lubricant , vibrators/dildos , dry agent 14 day prior enrolment duration trial . 9 . Documentation abnormality cervical cytology , include grossly bloody smear , within 90 day prior screen 10 . Willing refrain participation research trial duration trial 11 . Willing provide adequate locator information trial retention purpose reachable per local standard procedure , e.g . home visit telephone , via family close neighbour contact ( confidentiality maintain ) 12 . Willing agree abstain follow total 2 day ( 48 hour ) prior trial visit : Penilevaginal intercourse Oral contact genitalia 13 . Hepatitis B C negative time enrolment . 1 . Currently pregnant last pregnancy outcome within 3 month prior screen 2 . Currently breastfeed 3 . Currently within two month participation clinical research trial involve investigational market product prior screen 4 . Untreated symptomatic urogenital infection , e.g . urinary tract sexually transmitted infection , gynaecological condition vaginal itching , pain , discharge , within 2 week prior enrolment 5 . Have Grade 2 high pelvic examination finding , accord DAIDS Table Grading Severity Adult Pediatric Adverse Events ; Addendum 1 Female Genital Grading Table Use Microbicide Studies 6 . History significant urogenital uterine prolapse , undiagnosed vaginal bleeding , urethral obstruction , incontinence urge incontinence 7 . Current vulvar vaginal symptoms/abnormalities could influence trial result 8 . Cervical cytology screen require cryotherapy , biopsy , treatment ( infection ) , evaluation 9 . Symptomatic genital herpes simplex virus ( HSV ) infection history genital herpetic infection 10 . Any Grade 2 , 3 4 haematology , biochemistry urinalysis laboratory abnormality baseline ( screen ) accord DAIDS Table Grading Severity Adult Pediatric Adverse Events ; Addendum 1 Female Genital Grading Table Use Microbicide Studies 11 . Unexplained , abnormal bleed per vagina follow vaginal intercourse , gynaecologic surgery within 90 day prior enrolment 12 . Any history anaphylaxis severe allergy result angioedema ; history sensitivity/allergy latex silicone 13 . Any serious acute , chronic progressive disease ( e.g . know history neoplasm , cancer , diabetes , epilepsy , cardiac disease , autoimmune disease , HIV , AIDS , blood dyscrasia ) , sign cardiac disease , renal failure , severe malnutrition 14 . Have undergone hysterectomy 15 . Any condition ( ) , opinion Investigator , might interfere adherence trial requirement evaluation trial objective .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>